Cargando…
Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation
Nasal potential difference (NPD) is used as a biomarker of the cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial sodium channel (ENaC) activity. We evaluated methods to detect changes in chloride and sodium transport by NPD based on a secondary analysis of a Phase II CFTR-mod...
Autores principales: | Rowe, Steven M., Liu, Bo, Hill, Aubrey, Hathorne, Heather, Cohen, Morty, Beamer, John R., Accurso, Frank J., Dong, Qunming, Ordoñez, Claudia L., Stone, Anne J., Olson, Eric R., Clancy, John P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724869/ https://www.ncbi.nlm.nih.gov/pubmed/23922647 http://dx.doi.org/10.1371/journal.pone.0066955 |
Ejemplares similares
-
Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults
por: Kim, Jeeyeon, et al.
Publicado: (2018) -
Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation
por: Bernarde, Cédric, et al.
Publicado: (2015) -
The use of ivacaftor in CFTR mutations resulting in residual functioning protein
por: Guigui, S., et al.
Publicado: (2016) -
A Little CFTR Goes a Long Way: CFTR-Dependent Sweat Secretion from G551D and R117H-5T Cystic Fibrosis Subjects Taking Ivacaftor
por: Char, Jessica E., et al.
Publicado: (2014) -
Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial
por: Quittner, Alexandra, et al.
Publicado: (2015)